痴呆症的新疗法。神话、魔法与科学。
New treatments for dementia. Myth, magic, and science.
作者信息
Ganesan R, Standish T, Molloy D W, Darzins P, Orange J B
机构信息
McMaster University in Hamilton, Ont.
出版信息
Can Fam Physician. 1994 Jun;40:1149-57.
Abstract
Dementia could affect 778,000 Canadians by the year 2031. While current treatment is mainly supportive, a race to find new treatments for this dreaded disease takes varied approaches and currently accounts for 10% of drug company resources. Tacrine is the first drug licensed by the US Food and Drug Administration for use in Alzheimer's disease. New treatments raise several ethical issues and involve society's attitude toward death and dying.
摘要
到2031年，痴呆症可能会影响77.8万加拿大人。虽然目前的治疗主要是支持性的，但寻找这种可怕疾病新疗法的竞赛采用了多种方法，目前占制药公司资源的10%。他克林是美国食品药品监督管理局批准用于治疗阿尔茨海默病的第一种药物。新疗法引发了几个伦理问题，也涉及社会对死亡的态度。
相似文献
1
New treatments for dementia. Myth, magic, and science.痴呆症的新疗法。神话、魔法与科学。
Can Fam Physician. 1994 Jun;40:1149-57.
2
Canadian study of health and aging: study methods and prevalence of dementia.加拿大健康与老龄化研究：研究方法及痴呆症患病率
CMAJ. 1994 Mar 15;150(6):899-913.
3
The pharmacological effects of ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine.与他克林相比，植物提取物银杏叶对痴呆患者大脑的药理作用。
Psychopharmacol Bull. 1998;34(3):391-7.
4
Geriatric ethics: dementia and the quality of life.老年伦理学：痴呆与生活质量
Kans Med. 1994 Jul;95(7):174-5.
5
Dying with dementia: the views of family caregivers about quality of life.在痴呆症中离世：家庭照料者对生活质量的看法。
Australas J Ageing. 2008 Jun;27(2):89-92. doi: 10.1111/j.1741-6612.2008.00282.x.
6
[Ethical and legal issues in late stage of dementia].[痴呆晚期的伦理与法律问题]
Acta Med Port. 2008 Jan-Feb;21(1):65-71. Epub 2008 Apr 18.
7
Tacrine granted marketing approval for Alzheimer's disease.
Clin Pharm. 1993 Dec;12(12):873, 876.
8
Attitudes of physicians, nurses and relatives towards end-of-life decisions concerning nursing home patients with dementia.医生、护士及亲属对患有痴呆症的疗养院患者临终决策的态度。
Patient Educ Couns. 2006 Jun;61(3):372-80. doi: 10.1016/j.pec.2005.04.016. Epub 2005 Jun 21.
9
Developing treatment guidelines for Alzheimer's disease and other dementias.制定阿尔茨海默病及其他痴呆症的治疗指南。
J Clin Psychiatry. 1996;57 Suppl 14:37-8.
10
Improving the quality of care for mild to moderate dementia: an evaluation of the Croydon Memory Service Model.提高轻至中度痴呆症的护理质量：克罗伊登记忆服务模式评估
Int J Geriatr Psychiatry. 2007 Aug;22(8):782-8. doi: 10.1002/gps.1741.
本文引用的文献
1
"Smart-drug, smart-food" fad winning converts despite scientists' scepticism.尽管科学家们持怀疑态度，“聪明药、聪明食品”热潮仍在不断吸引追随者。
CMAJ. 1993 Feb 15;148(4):616-8.
2
Death gives birth to the nervous system. But how?
Science. 1993 Feb 5;259(5096):762-3. doi: 10.1126/science.8430328.
3
Effect of a new nootropic agent, CGS 5649B, on cognition, function, and behavior in dementia.新型促智药CGS 5649B对痴呆患者认知、功能及行为的影响
J Gen Intern Med. 1993 Aug;8(8):444-7. doi: 10.1007/BF02599624.
4
L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial.L-司来吉兰治疗轻度阿尔茨海默型痴呆：一项15个月试验的结果
J Am Geriatr Soc. 1993 Nov;41(11):1219-25. doi: 10.1111/j.1532-5415.1993.tb07306.x.
5
Treatment for life-threatening illness.危及生命疾病的治疗。
N Engl J Med. 1993 Sep 2;329(10):736. doi: 10.1056/NEJM199309023291015.
6
Effect of cholinergic and anticholinergic drugs on short-term memory in Alzheimer's dementia: a neuropsychological and computerized electroencephalographic study.胆碱能和抗胆碱能药物对阿尔茨海默病性痴呆短期记忆的影响：一项神经心理学和计算机化脑电图研究。
Clin Neuropharmacol. 1983;6(4):311-23. doi: 10.1097/00002826-198312000-00005.
7
The efficacy of the cerebral metabolic enhancers in the treatment of senile dementia.
Psychopharmacol Bull. 1983 Spring;19(2):212-9.
8
Nootropics: status and prospects.益智药：现状与前景。
Biol Psychiatry. 1983 May;18(5):521-3.
9
Comparative study of caffeine with other stimulants in university students.咖啡因与其他兴奋剂对大学生影响的对比研究。
Act Nerv Super (Praha). 1972;14(2):138-9.
10
Prevalence of severe dementia in Finland.
Neurology. 1985 Jul;35(7):1025-9. doi: 10.1212/wnl.35.7.1025.
Zotero 插件